ADMA Biologics Inc (ADMA) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

Total Assets Chart for ADMA Biologics Inc

ADMA Biologics Inc (ADMA) total assets for FY2025 were USD 624.2M, a 27.7% change from FY2024. ADMA Biologics Inc's total assets grew from USD 14.7M in 2006 to USD 624.2M in 2025 (4160.5% over 19 years). Total assets compound annual growth rate: 5-year CAGR of 24.6%, 10-year CAGR of 38.7%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$2.39B
Implied Share Price
$10.68
Enterprise Value
$2.24B
Revenue (TTM)
$512.28M
EBITDA
$224.19M
Profit Margin
32.98%
Trailing P/E
15.26
Forward P/E
9.78
Price/Book (MRQ)
5.32
Price/Sales (TTM)
4.67
EV/EBITDA
9.61
EV/Revenue
4.37
Dividend Yield
—
Book Value
$1.81
Free Cash Flow (FY2025)
$27.82M
Free Cash Flow Yield
1.16%

Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.